New study supports safety and efficacy of Evekeo for treating children with ADHD

(Mary Ann Liebert, Inc./Genetic Engineering News) The amphetamine-based drug Evekeo, given once or twice daily to children 6-12 years of age, is effective in treating attention-deficit/hyperactivity disorder (ADHD) symptoms and improving performance in a laboratory classroom setting, according to the results of a new study published in the Journal of Child and Adolescent Psychopharmacology.